Comments on:

FDA panel backs Gilead Sciences' hepatitis C drug

Back to the article » |
WASHINGTON (AP) — Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions of Americans infected with the liver-destroying virus. All 15 members of the FDA's panel of virus experts voted to recommend approval of Gilead's pill, sofosbuvir, to treat several forms of hepatitis C. The FDA...

To learn more about commenting on and our community guidelines, please see our comments FAQ.